ibrutinib and fcr chemoimmunotherapy: improving complete remission in cll patients?
Published 6 years ago • 118 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:55
a model including cd49d expression to predict outcomes in patients with cll treated with ibrutinib
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:47
ianalumab add-on therapy in cll patients receiving ibrutinib
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
11:51
uncw clr interim analyses and study closeout
-
5:52
the power of venetoclax
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
4:29
first-line ibrutinib vs chemoimmunotherapy in cll: a real-world data analysis
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
2:51
genetic markers in patients with early-stage cll treated with ibrutinib: findings from cll12
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:42
the future of cll treatment: aiming for long-lasting remission